What Phoenix Tissue Repair does

Phoenix Tissue Repair is a private, early-stage biotechnology company founded in 2017 and headquartered in Boston, Massachusetts. According to its firmographic profile, the company is focused on advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare inherited skin disorder characterized by skin fragility and chronic blistering. The company operates with a small team of 1-10 employees, consistent with a research-stage biotech organization.

The bulk of the source content provided alongside this analysis pertains to BridgeBio Pharma, Inc., a separate late-stage pharmaceutical company with three FDA-approved products (Attruby/acoramidis and NULIBRY/fosdenopterin) and an investigational pipeline targeting multiple rare genetic diseases including ATTRv amyloidosis, LGMD2I/R9, ADH1, achondroplasia, hypochondroplasia, and Canavan disease. No product-level, financial, leadership, partnership, or strategic-move information specific to Phoenix Tissue Repair is disclosed in the input data beyond the firmographic profile. The relationship between Phoenix Tissue Repair and BridgeBio is not explicitly stated, and no underlying technology platform, business model, pricing, or revenue mechanics for Phoenix Tissue Repair can be characterized from the provided evidence.

Name

Phoenix Tissue Repair

Legal name

BridgeBio Pharma, Inc.

Website

https://phoenixtissuerepair.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Phoenix Tissue Repair is a private, early-stage Boston-based biotechnology company founded in 2017 that is developing a novel treatment for Dystrophic Epidermolysis Bullosa, a rare inherited skin disorder.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Rare disease therapeutics
• Epidermolysis bullosa treatment
• Biopharmaceutical development
• Genetic skin disorder
• Orphan drug development

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Distribution channels2 records

Marketing channels6 records

Core offering

Phoenix Tissue Repair is a biotechnology company advancing a novel treatment for Dystrophic Epidermolysis Bullosa (DEB), a rare genetic skin disorder characterized by fragile skin and chronic blistering. The company is developing an investigational therapeutic candidate targeting this rare disease.

Product overview

The source data provided pertains to BridgeBio Pharma, Inc. (bridgebio.com), not Phoenix Tissue Repair. No product or service information about Phoenix Tissue Repair is present in the provided source content.

Differentiator

Problem solved

Functional benefit

Brands

• Attruby (acoramidis): FDA-approved medicine for transthyretin amyloidosis (ATTRv)
• NULIBRY (fosdenopterin)
• On Rare Podcast

Quantifiable outcome

• $8 billion peak year sales potential

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Direct peers

• Abeona Therapeutics: Abeona Therapeutics has historically developed EB-101 (prademagene zamikeracel), an autologous gene-corrected cell therapy for recessive dystrophic EB. It targets the same DEB patient population with a similar disease-modifying mechanism, making it a direct clinical-stage competitor to Phoenix Tissue Repair.
• Castle Creek Biosciences: Castle Creek Biosciences develops FCX-007, a gene-modified autologous fibroblast therapy for dystrophic EB, and operates in the same DEB regulatory and clinical landscape as Phoenix Tissue Repair, with comparable modality and patient population focus.
• Krystal Biotech: Krystal Biotech developed and commercialized Vyjuvek (beremagene geperpavec), the first FDA-approved gene therapy for Dystrophic Epidermolysis Bullosa. It is the most directly comparable company to Phoenix Tissue Repair given overlapping indication, modality (genetic correction of skin fragility), and target patient population in DEB.
• Fibrocell Science: Fibrocell Science has historically developed autologous fibroblast-based therapies for rare skin and connective tissue disorders, including programs targeting dystrophic EB. Its therapeutic modality and target indications overlap directly with Phoenix Tissue Repair's regenerative skin approach.
• Holostem Terapie Avanzate: Holostem Terapie Avanzate developed and commercializes Holoclar, an autologous limbal stem cell therapy for corneal regeneration, and has worked on epithelial stem cell therapies applicable to severe skin-fragility disorders. Its expertise in advanced-therapy medicinal products for skin and epithelial regeneration is directly comparable to Phoenix Tissue Repair's regenerative approach to DEB.

Broad incumbents

• BridgeBio Pharma: BridgeBio Pharma is the parent organization whose data fields appear in the provided dump and which houses multiple rare-disease subsidiaries including Phoenix Tissue Repair. It is a broader incumbent in rare genetic disease drug development with 3 FDA approvals, providing regulatory and capital infrastructure relevant to Phoenix Tissue Repair's program.
• Chiesi Farmaceutici: Chiesi (which acquired Amryt Pharma) is a broad rare-disease pharmaceutical company with commercial infrastructure in dermatology and orphan disease distribution. It represents a plausible strategic acquirer or commercialization partner comparable to Phoenix Tissue Repair's likely commercial pathway.
• Astellas Gene Therapies: Astellas Gene Therapies (formerly Audentes) develops AAV-based gene therapies for rare genetic disorders and has active programs in neuromuscular and metabolic disease. As a large rare-disease incumbent with gene therapy infrastructure, it is comparable to the eventual scale-up pathway that Phoenix Tissue Repair may pursue under BridgeBio or independently.

Emerging players

• Rznomics: Rznomics is developing RNA-based regenerative and gene-regulating therapies for rare diseases including programs targeting skin and connective-tissue disorders. Its emerging pipeline and rare-disease focus overlap with Phoenix Tissue Repair's single-indication, advanced-therapy profile.
• REGENXBIO: REGENXBIO develops AAV-based gene therapies for rare diseases including ophthalmology and metabolic disorders, with platform technology applicable to skin and connective tissue indications. Its modality overlap and rare-disease development focus make it a relevant emerging peer to Phoenix Tissue Repair.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/BridgeBioPharma
• YouTubeyoutube.com/@BridgeBioPharma
• Facebookfacebook.com/bridgebiopharma
• LinkedInlinkedin.com/company/bridgebio
• Instagraminstagram.com/bridgebiopharma
• TikToktiktok.com/@bridgebiopharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phoenix Tissue Repair